Hansa Biopharma
Lund
About Hansa Biopharma
Hansa Biopharma is a biopharmaceutical company that develops immunomodulatory treatments for people living with rare immunological diseases. They concentrate on creating novel, life-saving and life-changing treatments that can meet the critical, unmet medical needs of individuals with uncommon immunological disorders. To target pathogenic or disease-causing antibodies, they developed its proprietary antibody-cleaving enzyme technology platform. The company's diverse therapeutic pipeline has the potential to address significant unmet medical needs in transplantation, autoimmune diseases, gene therapy, and oncology indications.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $205.2M
- Funding stage: IPO
- Last round: Post-IPO Debt (Mar 2026)
- Ticker: sto:HNSA
- Website: hansabiopharma.com
- Phone: +46 46 16 56 70
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/hansa-biopharma-121226 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.